Verona Pharma plc Verona Pharma Plc : Block Listing Interim Review

 
TIDMVRP TIDMVRP 
 
 
   LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, provides the following update on its block 
listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for 
Companies, regarding its existing block listing arrangements, put in 
place from 29 July 2016: 
 
 
 
 
Name of applicant:                                           Verona Pharma plc 
Name of scheme:                                              2016 Warrant 
                                                             Shares 
Period of return:                                            From 3 May 2017 
                                                             to 30 November 
                                                             2017 
Balance of unallotted securities under scheme(s) from        12,446,370 
 previous return:                                            Ordinary Shares 
                                                             of 5 pence each 
Plus: The amount by which the block scheme(s) has            Nil 
 been increased since the date of the last Review (if 
 any increase has been applied for): 
Less: Number of securities issued/allotted under scheme(s)   Nil 
 during period 
Equals: Balance under scheme(s) not yet issued/allotted      12,446,370 
 at end of period:                                           Ordinary Shares 
                                                             of 5 pence each 
Number and class of share(s) (amount of stock/debit          10,262,879 on 29 
 securities) originally admitted and the Date of Admission:  July 2016 
 
 
 
 
Name of contact:                   Claire Poll 
Telephone number of contact:   [phone] 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker)                                     [e-mail] 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. 
 
   Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as 
both a bronchodilator and an anti-inflammatory agent in a single 
compound. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), 
and potentially asthma. 
 
   Verona Pharma's shares are traded on the London AIM market under the 
symbol VRP.L. Further information on Verona Pharma can be found at 
http://www.veronapharma.com/ 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

November 30, 2017 13:52 ET (18:52 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.